How to Help Your Patients Find Intralipid in Stock: A Provider's Guide

When a home parenteral nutrition (PN) patient calls your office because their home infusion pharmacy can't fill their Intralipid prescription, it creates an urgent clinical workflow challenge. Unlike many drug access problems, Intralipid supply issues can have serious patient safety implications — these patients often have no alternative nutritional route. This guide provides a step-by-step clinical workflow for helping patients find Intralipid quickly.

Why Intralipid Access Issues Require Immediate Provider Action

Patients on home PN often have no other nutritional option — short bowel syndrome, intestinal failure, or GI dysmotility may make oral or enteral feeding impossible. For these patients, losing access to Intralipid (and PN overall) for even 24-48 hours can lead to:

Hypoglycemia (especially in patients with no enteral caloric intake)

Electrolyte imbalances

Accelerated malnutrition in already-compromised patients

Dehydration and hospital readmission

Treat any Intralipid access gap as a clinical urgency. The following workflow helps you resolve it systematically.

Step 1: Authorize Formulary Flexibility Proactively

The most effective intervention is one that happens before the shortage occurs. When writing PN orders for home patients, consider adding a formulary note such as: "SMOFlipid 20% acceptable as substitute for Intralipid 20% if Intralipid is unavailable." This gives the home infusion pharmacy permission to substitute without calling you for an urgent authorization during a supply crisis.

Ensure your prescribing team knows which IV lipid emulsions are clinically equivalent for each patient population you manage. As a general rule:

Adults without PNALD risk: Intralipid, SMOFlipid, or Clinolipid are generally interchangeable at the prescriber's discretion

Pediatric patients at risk for PNALD: SMOFlipid is preferred over Intralipid at most major centers

Pediatric patients with established PNALD: Omegaven per institutional protocol

Step 2: Identify Backup Home Infusion Pharmacies in Advance

Don't wait for a supply crisis to identify alternative home infusion pharmacies. Maintain a list of at least 2-3 home infusion providers in your area that are:

Licensed to compound TPN in your state

Enrolled with your patients' major insurance plans (Medicare, Medicaid, and major commercial payers)

Capable of delivering refrigerated products to your patient population's service area

National home infusion providers to consider: Option Care Health, Coram CVS Specialty Infusion Services, BioMatrix, and Accredo (Evernorth). For critical patients, consider establishing dual-pharmacy relationships proactively.

Step 3: Ensure Patients Have Complete Documentation

A common barrier to pharmacy transfer is incomplete or outdated documentation. Ensure your home PN patients have current versions of:

Detailed PN prescription (with all components and concentrations, not just Intralipid)

Clinical documentation supporting medical necessity of PN (diagnosis, ICD-10 codes, failure of enteral feeding documentation)

Most recent labs: triglycerides, LFTs, BMP, CBC, prealbumin

Insurance information and prior authorization numbers

Step 4: Use medfinder for Providers to Check Pharmacy Stock

medfinder for Providers streamlines the process of finding Intralipid in stock near your patients. Instead of having your staff call multiple home infusion pharmacies individually, medfinder.com/providers contacts pharmacies on your behalf and reports which ones have the medication in stock and can fill the prescription. Results are sent via text, allowing your clinical team to act quickly.

Step 5: Know When to Admit

If Intralipid (or an acceptable alternative) cannot be sourced within 24-48 hours for a patient with no enteral access, hospital admission for IV nutritional support should be strongly considered. In a hospital setting, Intralipid is dispensed through the central pharmacy — a completely different supply chain from home infusion. This can bridge the patient while outpatient pharmacy access is secured.

For more on the clinical shortage landscape, see: Intralipid shortage: what providers and prescribers need to know in 2026.